Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

- Roche progresses R1626 into phase IIb study, called POLI 1 -

BOSTON, Nov. 2 /PRNewswire/ -- R1626, one of Roche's new investigational drugs for chronic hepatitis C virus (HCV) infection, has shown promising antiviral activity when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) (ribavirin), according to results being presented at the American Association for the Study of the Liver Disease (AASLD) meeting, being held in Boston, Nov. 2-6. After four weeks of treatment with this triple combination, the virus could no longer be detected in up to 81 percent of patients, with a mean decrease in viral load of 5.2 log10 from baseline. This is indicative of a robust virological response, and R1626 is being progressed into Phase IIb study as a result of these findings.

R1626 belongs to a class of antivirals called polymerase inhibitors, which are being investigated in combination with the current standard of care, pegylated interferon and ribavirin. The hope is that this combination will increase the number of patients who are able to be successfully treated for hepatitis C.

"The results from this Phase IIa study show that R1626 has a profound antiviral effect when used in combination with PEGASYS plus COPEGUS," said Dr. Paul Pockros, Scripps Clinic, San Diego, California, the lead investigator of the study. "This effect of R1626 in combination therapy, along with the lack of resistance observed to date, means that R1626 could be an exciting drug for patients with hepatitis C, if a safe and acceptable dosing regimen can be determined in future studies."

Antiviral Activity and Safety Results Being Presented at AASLD

The multicenter Phase IIa study enrolled patients with genotype 1 chronic HCV who have not previously received treatment. The objectives were to evaluate the four-week activity and safety of combining R1626 with PEGASYS alone or R1626 with PEGASYS plus COPEGUS in comparison to PEGASYS/COPEGUS,
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LAKE FOREST, Ill. , Dec. 19, 2014 /PRNewswire/ ... the world,s leading provider of injectable drugs and infusion ... the J.P. Morgan 33rd Annual Healthcare Conference on Wednesday, ... The presentation is scheduled to begin at 10:30 ... will be available to all interested parties through a ...
(Date:12/19/2014)... 2014 Radiology information system ... used to store, manipulate, and distribute patient radiological ... tracking and scheduling system, result reporting, and an ... HIS and other databases improves the hospital workflow. ... scheduling, patient list management, radiology department workflow management, ...
(Date:12/19/2014)... 18, 2014 Capnia, Inc. (NASDAQ: ... medical diagnostics based on its proprietary Sensalyze™ Technology ... announced financial results for the third quarter and ... "Following the completion of our initial public offering ... the recently initiated CoSense® commercial launch," said Anish ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... Inc. (Nasdaq: MYL ) today affirmed its commitment ... the developing world to high quality, affordable treatment. The company ... exhibition and reception today in Washington D.C. The event is ... Congressional HIV/AIDS Caucus. Mylan President Heather Bresch said: ...
... and GHENT, Belgium, December 1, 2011 ... Antibody Programs into Clinical Development arGEN-X, ... of human monoclonal antibodies from its proprietary SIMPLE Antibody™ ... million (USD 37 million) Series B fundraising round, which ...
Cached Medicine Technology:Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment 2Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment 3arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round 2arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round 3arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round 4
(Date:12/21/2014)... (PRWEB) December 21, 2014 Hundreds ... product liability claims involving a class of Type ... to move forward in a federal multidistrict litigation ... of California, Bernstein Liebhard LLP reports. According to ... established a data cut-off date of February 27, ...
(Date:12/21/2014)... 2014 Serious Buyer, Andrew Hawley from ... Morrison and the Doors International Ballroom at the Hilton ... be the only time that Morrison's mother would see ... 25, 1967. According to Hawley, “This would be the ... the Alexandria Roller Rink earlier that year and would ...
(Date:12/21/2014)... December 21, 2014 As testosterone ... heart attacks, stroke and blood clots from using testosterone ... a new study shows that the male hormone testosterone ... In a study published in the Proceedings of the ... Amos-Landgraf examined a group of male rats with naturally ...
(Date:12/20/2014)... BambooIndustry.com is a leading eco-friendly bamboo flooring ... bamboo flooring promotion for the coming 2015. , ... and offers the best bamboo products and services ... all customers can enjoy a special discount, up ... BambooIndustry.com from press releases. , The bamboo flooring ...
(Date:12/20/2014)... NY (PRWEB) December 20, 2014 ... allege a metal-on-metal version of the artificial hip ... in state and federal courts, Bernstein Liebhard LLP ... Jersey’ Bergen County Superior Court on December 2nd, ... to begin deposition of plaintiffs on November 19, ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4
... MUNDELEIN, Ill., Nov. 1 Z Trim Holdings, Inc.,(Amex: ... a Current Report on Form 8-K,with the Securities Exchange ... as a result of a determination by Z,Trim that ... the Company determined that its financial statements for the,quarters ...
... increases fatigue in children suggests that,altering timing or ... on,sleep and increase quality of life for patients ... The anti-leukemia,drug dexamethasone contributes to a relentless ... treatment for acute lymphoblastic leukemia,(ALL), according to a ...
... Nov. 1 Vital Images, Inc.,(Nasdaq: VTAL ), ... will present at the CIBC World,Markets 18th Annual Healthcare ... a.m. ET). Jay D. Miller, president and chief executive,officer, ... To access the Webcast, go to the investors, section ...
... the expensive but lifesaving devices, experts note , , THURSDAY, ... give cardiologists guidance about whether they should implant defibrillators ... Implanted defibrillators aren,t necessary for all patients and can ... at Mid-America Heart Institute in Kansas City who,s familiar ...
... Associate Professor of Medicine and Cancer Biology JeanMarie ... of the countrys most talented rising scientific stars ... recipients of the Presidential Early Career Award ... Award is the highest honor bestowed by the ...
... avoid need for a prescription, agency says , , THURSDAY, Nov. ... the Internet from foreign countries in an apparent effort to ... Thursday. , But many of these drugs are unregulated, posing ... despite the widespread belief that many imported drugs cost less ...
Cached Medicine News:Health News:Z Trim Holdings Reports Restatement of Previously Issued Financial Statements; Amends Bylaws 2Health News:Z Trim Holdings Reports Restatement of Previously Issued Financial Statements; Amends Bylaws 3Health News:Z Trim Holdings Reports Restatement of Previously Issued Financial Statements; Amends Bylaws 4Health News:Z Trim Holdings Reports Restatement of Previously Issued Financial Statements; Amends Bylaws 5Health News:St. Jude Finds Anti-Leukemia Drug Increases Patient Fatigue 2Health News:Vital Images to Present at the CIBC World Markets 18th Annual Healthcare Conference on Wednesday, November 7 2Health News:Test Spots Who Should Get Implanted Defibrillator 2Health News:JeanMarie Houghton, MD, PhD, recognized as one of nation's top young scientists 2Health News:JeanMarie Houghton, MD, PhD, recognized as one of nation's top young scientists 3Health News:Consumers Still Buying Risky Imported Drugs Online: FDA 2Health News:Consumers Still Buying Risky Imported Drugs Online: FDA 3
...
... The Tango exercise BP monitor is ... patient's systolic and diastolic BP along with ... designed specifically for use in treadmill, ergometer ... also ideal for use in research environments., ...
...
...
Medicine Products: